Paper20573153
Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches.
Coppola A and 2 others. Br J Haematol, 2010. Cited by 72 papers, by iCite.
Cite this record
ConductScience Library. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Papers, record 20573153. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20573153
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Factor VIII | Major topic |
| Hemophilia A | Major topic |
| Immune Tolerance | Major topic |
| Isoantibodies | Major topic |
| Evidence-Based Medicine | |
| Humans | |
| Male | |
| Patient Selection | |
| Prognosis |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT02479087 | Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients | Background |
Source ClinicalTrials.gov
Cited by25
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 72 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41890554 | Treatment outcomes, safety, and characteristics of immune tolerance induction in patients with hemophilia B and inhibitors: a systematic review. | Res Pract Thromb Haemost | 2026 | https://conductscience.org/library/papers/41890554 | PubMed |
| 39583653 | Rescue immune tolerance induction with a recombinant factor Fc-fused VIII: prospective ReITIrate study of clinical, humoral and cellular immune responses. | Ther Adv Hematol | 2024 | https://conductscience.org/library/papers/39583653 | PubMed |
| 39558913 | Prediction of the chance of successful immune tolerance induction in persons with severe hemophilia A and inhibitors: a clinical prediction model. | Res Pract Thromb Haemost | 2024 | https://conductscience.org/library/papers/39558913 | PubMed |
| 38565097 | Consensus-Based Expert Recommendations on the Management of Hemophilia A in the Gulf Region. | Acta Haematol | 2025 | https://conductscience.org/library/papers/38565097 | PubMed |
| 38524060 | A Study of Clinical Profile and Treatment in Adult Hemophilia Patients with Special Reference to the Inhibitor Levels. | Cureus | 2024 | https://conductscience.org/library/papers/38524060 | PubMed |
| 37192286 | Factor VIII trafficking to CD4+ T cells shapes its immunogenicity and requires several types of antigen-presenting cells. | Blood | 2023 | https://conductscience.org/library/papers/37192286 | PubMed |
| 35868021 | Management of haemophilia A with inhibitors: A regional cross-talk. | Haemophilia | 2022 | https://conductscience.org/library/papers/35868021 | PubMed |
| 34278191 | Low-dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors. | Res Pract Thromb Haemost | 2021 | https://conductscience.org/library/papers/34278191 | PubMed |
| 34262568 | Factor VIII-Fc Activates Natural Killer Cells via Fc-Mediated Interactions With CD16. | Front Immunol | 2021 | https://conductscience.org/library/papers/34262568 | PubMed |
| 32832483 | Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients. | Int J Mol Cell Med | 2020 | https://conductscience.org/library/papers/32832483 | PubMed |
| 32598171 | Clinical Care of Bone Health in Patients on the Immune Tolerance Induction's Protocols With an Immunosuppressive Agent for Inhibitor Eradication in Hemophilia. | Clin Appl Thromb Hemost | 2020 | https://conductscience.org/library/papers/32598171 | PubMed |
| 30865582 | New data from the Italian National Register of Congenital Coagulopathies, 2016 Annual Survey. | Blood Transfus | 2020 | https://conductscience.org/library/papers/30865582 | PubMed |
| 30545924 | Prevention of the anti-factor VIII memory B-cell response by inhibition of Bruton tyrosine kinase in experimental hemophilia A. | Haematologica | 2019 | https://conductscience.org/library/papers/30545924 | PubMed |
| 30411401 | Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients. | Eur J Haematol | 2019 | https://conductscience.org/library/papers/30411401 | PubMed |
| 28920105 | The impact of von Willebrand factor on factor VIII memory immune responses. | Blood Adv | 2017 | https://conductscience.org/library/papers/28920105 | PubMed |
| 26830966 | Early eradication of factor VIII inhibitor in patients with congenital hemophilia A by immune tolerance induction with a high dose of immunoglobulin. | Int J Hematol | 2016 | https://conductscience.org/library/papers/26830966 | PubMed |
| 25548513 | A new recombinant factor VIII: from genetics to clinical use. | Drug Des Devel Ther | 2014 | https://conductscience.org/library/papers/25548513 | PubMed |
| 25350962 | Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. | Blood Transfus | 2014 | https://conductscience.org/library/papers/25350962 | PubMed |
| 24922295 | Current and evolving features in the clinical management of haemophilia. | Blood Transfus | 2014 | https://conductscience.org/library/papers/24922295 | PubMed |
| 24333314 | Clinical use of factor VIII and factor IX concentrates. | Blood Transfus | 2013 | https://conductscience.org/library/papers/24333314 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| F8 | 2157 | PubTator's text mining | https://conductscience.org/library/genes/2157 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20573153
GET https://conductscience.org/api/papers/v1/20573153/cited_by?page=2